SecBot SecBot
Biotech Drug Report Generated Nov 9, 2026

prasinezumab

PRTA·PROTHENA CORP PUBLIC LTD CO
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 3
Time to market
Phase 3 primary completion is expected in 2029. If successful, regulatory filing and potential approval would likely follow in 2030-2031 at the earliest.
Why 4/10
No hard dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled within the next ~12 months. The Phase 3 primary completion is expected in 2029. The drug is partnered with Roche, so Prothena's share-price sensitivity to this single asset is moderated by its other pipeline programs and cash position.
Actionable Insight NEUTRAL

The next major catalyst for prasinezumab is the Phase 3 primary completion expected in 2029, which is years away. In the nearer term, watch for any interim data updates from Roche's Phase 3 program or additional exploratory analyses presented at medical conferences. Prothena's nearer-term binary catalyst is the moponetug Phase 2 data readout expected in 1H 2027.

Price Chart

Loading chart...

Executive Summary

Prasinezumab is an investigational anti-alpha-synuclein monoclonal antibody for early-stage Parkinson's disease, developed by Prothena (PRTA) in partnership with Roche. The Phase IIb PADOVA study (586 patients) missed its primary endpoint in December 2024, but Roche decided to advance the drug into Phase III development in June 2025 based on numerical trends and exploratory signals suggesting possible benefit, particularly in patients with rapidly progressing disease. Phase 3 trials are underway with primary completion expected in 2029, meaning no near-term binary catalyst. Prothena has $272.2M cash, no debt, and a market cap around $421M. The stock trades near its 52-week low of $7.73, with a major insider buying aggressively in recent months.

How It Works

Prasinezumab is an intravenous monoclonal antibody designed to target and help clear clumps of alpha-synuclein protein in the brain. In Parkinson's disease, alpha-synuclein misfolds and aggregates into toxic clumps (Lewy bodies) that damage neurons. Prasinezumab aims to bind to these aggregated proteins and tag them for removal by the immune system, potentially slowing disease progression.

Trial Status

Prasinezumab is in Phase 3 development for early-stage Parkinson's disease, following the Phase IIb PADOVA study (586 patients) that missed its primary endpoint but showed numerical trends. Roche initiated Phase 3 in mid-2025. Prothena's Q3 2026 earnings report indicates Phase 3 primary completion is expected in 2029. Partner presentations at AD/PD 2026 conference in March 2026 covered clinical updates on prasinezumab.

The Two-Sided Case

▲ Bull Case5
Roche, a top-tier pharma partner, decided to advance prasinezumab into Phase 3 after reviewing the Phase IIb data, signaling confidence in the drug's potential despite the missed primary endpoint.
Exploratory analyses published in Nature Medicine suggested prasinezumab may slow motor progression in patients with rapidly progressing Parkinson's disease, a potentially addressable subpopulation.
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody targeting a known pathological driver of Parkinson's disease, with a large addressable market if approved.
Prothena has $272.2M in cash with no debt, providing runway through 2029 without near-term dilution risk.
Major 10% owner William P. Scully has been aggressively buying shares ($7M+ in purchases since September 2026), signaling insider conviction at current prices around $8.
▼ Bear Case5
The Phase IIb PADOVA study missed its primary endpoint, raising questions about whether the drug provides meaningful clinical benefit. Phase 3 is not guaranteed to succeed.
Phase 3 primary completion is not expected until 2029, meaning no near-term binary catalyst and a long wait for potential commercialization.
Prothena has no approved products and relies entirely on partner milestones and collaboration payments for revenue. The recent BMS termination of the PRX019 deal removed up to $617.5M in potential milestones.
The stock has fallen 36.8% over the past year, reflecting pipeline setbacks and investor skepticism about the partnered programs.
Analyst coverage is stale (last action May 2026), and the mean price target of $21.40 may not reflect current risks.

Upcoming Catalysts

  • Phase 3 primary completion expected in 2029 (no near-term binary catalyst)
  • Potential interim data or exploratory analyses presented at medical conferences
  • Moponetug Phase 2 data readout expected in 1H 2027 (separate Prothena program)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PROTHENA CORP PUBLIC LTD CO 8-K PRTA ·Originating report

Sources · 7

Hover a chip for the title
1 businesswire.com2 businesswire.com3 news-medical.net4 sec.gov5 markets.financialcontent.com6 msn.com7 nasdaq.com